Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe
Other stock markets
 07:31:28 2024-07-03 am EDT 		5-day change 1st Jan Change
1,724 DKK +0.25% Intraday chart for Genmab A/S -3.77% -20.02%
Jun. 28 Would you like some more inflation? Our Logo
Jun. 28 Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Genmab A/S - Epcoritamab Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed, Refractory Follicular Lymphoma
AQ
Genmab A/S - Completion of Share Buy-back Program
AQ
Would you like some more inflation?
Our Logo
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
MT
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
BU
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GL
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
CI
Genmab Closes DKK3.5 Billion Share Buyback Early
MT
Completion of Share Buy-back Program
GL
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma
AQ
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma
AQ
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating
MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
MT
Genmab Wins US Approval for Follicular Lymphoma Treatment
MT
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
BU
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GL
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY
CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
CI
AbbVie Gets New FDA Accelerated Approval for Epkinly
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. News Genmab A/S